Chapter 21. Diabetes Mellitus

  1. Donald A. Molony MD3,4 and
  2. Jonathan C. Craig MD, PhD5,6
  1. Piero Ruggenenti MD1 and
  2. Giuseppe Remuzzi MD, FRCP2

Published Online: 4 MAR 2009

DOI: 10.1002/9781444303391.ch21

Evidence-Based Nephrology

Evidence-Based Nephrology

How to Cite

Ruggenenti, P. and Remuzzi, G. (2008) Diabetes Mellitus, in Evidence-Based Nephrology (eds D. A. Molony and J. C. Craig), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444303391.ch21

Editor Information

  1. 3

    Division of Renal Disease and Hypertension, University of Texas, USA

  2. 4

    Houston Medical School, Houston, Texas, USA

  3. 5

    School of Public Health, University of Sydney, Australia

  4. 6

    Department of Nephrology, The Children's Hospital at Westmead, Sydney, Australia

Author Information

  1. 1

    Unit of Nephrology, Azienda Ospedaliera Ospedali Riuniti di Bergamo, 24128, Bergamo, Italy

  2. 2

    Clinical Research Center for Rare Diseases, “Aldo & Cele Daccò,” Mario Negri Institute for Pharmacological Research, Bergamo, Italy

Publication History

  1. Published Online: 4 MAR 2009
  2. Published Print: 5 DEC 2008

ISBN Information

Print ISBN: 9781405139755

Online ISBN: 9781444303391



  • diabetes mellitus;
  • diabetic nephropathy and time-dependent changes in GFR and albuminuria;
  • epidemics of type 2 diabetes;
  • protecting target organs in people with diabetes and kidney disease;
  • inhibition of RAAS;
  • risks and benefits of antialdosterone therapy;
  • MicroAlbuminuria Reduction with Valsartan (MARVAL) study;
  • intensified blood pressure control;
  • preventing kidney disease in people with diabetes


This chapter contains sections titled:

  • Introduction

  • The epidemics of type 2 diabetes and related renal and cardiovascular disease

  • Diabetic renal disease

  • The cardio-renal syndrome

  • Protecting target organs in people with diabetes and kidney disease

  • Inhibition of the RAAS

  • Role of calcium channel blockade: class effects of dihydropyridine and nondihydropyridine calcium antagonists

  • Role of intensified blood pressure control

  • Preventing kidney disease in people with diabetes

  • Conclusions

  • References